Antipsychotic use in older adults with Parkinson's disease
Identifieur interne : 002500 ( Main/Curation ); précédent : 002499; suivant : 002501Antipsychotic use in older adults with Parkinson's disease
Auteurs : Connie Marras [Canada] ; Alexander Kopp [Canada] ; Feng Qiu [Canada] ; Anthony E. Lang [Canada] ; Kathy Sykora [Canada] ; Kenneth I. Shulman [Canada] ; Paula A. Rochon [Canada]Source :
- [ 0885-3185 ]
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antipsychotic, Antipsychotic Agents (therapeutic use), Cohort Studies, Databases, Factual (statistics & numerical data), Drug Utilization Review (statistics & numerical data), Female, Geriatric Assessment, Humans, Incidence, Male, Nervous system diseases, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson disease, Psychosis, Psychotic Disorders (drug therapy), Psychotic Disorders (epidemiology), Psychotic Disorders (etiology).
- MESH :
- chemical , therapeutic use : Antipsychotic Agents.
- complications : Parkinson Disease.
- drug therapy : Parkinson Disease, Psychotic Disorders.
- epidemiology : Parkinson Disease, Psychotic Disorders.
- etiology : Psychotic Disorders.
- statistics & numerical data : Databases, Factual, Drug Utilization Review.
- Aged, Aged, 80 and over, Cohort Studies, Female, Geriatric Assessment, Humans, Incidence, Male.
Abstract
The choice of agents to treat psychotic symptoms in Parkinson's disease is important given the potential for antipsychotics to worsen Parkinsonism. The purpose of this study was to estimate the incidence of psychotic symptoms requiring treatment in individuals with Parkinson's disease after starting dopaminergic medications, and to describe the agents being selected as initial antipsychotic therapy. Using the administrative health care databases of Ontario, Canada, individuals 66 years of age or older with Parkinson's disease who were newly treated with dopaminergic agents were identified. Subsequent prescriptions for antipsychotic medications were then identified. A total of 10,347 older adults were newly started on dopaminergic agents between 1998 and 2003. The Kaplan–Meier estimate for the cumulative probability of requiring an antipsychotic at 7 years was 35%; 499 individuals (4.8%; 5.2/100 person–years) were prescribed an antipsychotic within 1 year of starting dopaminergic therapy. The proportion of initial antipsychotic prescriptions for typical antipsychotics decreased from 56% (42 of 75) in 1998 to 9% (8 of 88) in 2002. Antipsychotic use is common in individuals with Parkinsonism newly treated with dopaminergic medication. Typical antipsychotics are still commonly being chosen as first‐line agents for older patients, indicating a need for interventions to improve practice. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21192
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000046
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000046
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000978
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001094
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001094
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001094
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000712
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000712
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000712
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :002743
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000762
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000558
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000674
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :002964
Links to Exploration step
ISTEX:0C3F9C4EA52476687FAD7642CB4ED5E3CF6DD2D6Le document en format XML
<record><TEI wicri:istexFullTextTei="no"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antipsychotic use in older adults with Parkinson's disease</title>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
</author>
<author><name sortKey="Kopp, Alexander" sort="Kopp, Alexander" uniqKey="Kopp A" first="Alexander" last="Kopp">Alexander Kopp</name>
</author>
<author><name sortKey="Qiu, Feng" sort="Qiu, Feng" uniqKey="Qiu F" first="Feng" last="Qiu">Feng Qiu</name>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</author>
<author><name sortKey="Sykora, Kathy" sort="Sykora, Kathy" uniqKey="Sykora K" first="Kathy" last="Sykora">Kathy Sykora</name>
</author>
<author><name sortKey="Shulman, Kenneth I" sort="Shulman, Kenneth I" uniqKey="Shulman K" first="Kenneth I." last="Shulman">Kenneth I. Shulman</name>
</author>
<author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:0C3F9C4EA52476687FAD7642CB4ED5E3CF6DD2D6</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/mds.21192</idno>
<idno type="url">https://api-v5.istex.fr/document/0C3F9C4EA52476687FAD7642CB4ED5E3CF6DD2D6/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000046</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000046</idno>
<idno type="wicri:Area/Istex/Curation">000046</idno>
<idno type="wicri:Area/Istex/Checkpoint">000978</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000978</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Marras C:antipsychotic:use:in</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17149718</idno>
<idno type="wicri:Area/PubMed/Corpus">001094</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001094</idno>
<idno type="wicri:Area/PubMed/Curation">001094</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001094</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001094</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001094</idno>
<idno type="wicri:Area/Ncbi/Merge">000712</idno>
<idno type="wicri:Area/Ncbi/Curation">000712</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000712</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Marras C:antipsychotic:use:in</idno>
<idno type="wicri:Area/Main/Merge">002743</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:07-0181687</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000762</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000558</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000674</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000674</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Marras C:antipsychotic:use:in</idno>
<idno type="wicri:Area/Main/Merge">002964</idno>
<idno type="wicri:Area/Main/Curation">002500</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Centre, Toronto Western Hospital, 7 McL, 399 Bathurst Street, Toronto, ON M5T 2S8</wicri:regionArea>
<wicri:noRegion>ON M5T 2S8</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kopp, Alexander" sort="Kopp, Alexander" uniqKey="Kopp A" first="Alexander" last="Kopp">Alexander Kopp</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Qiu, Feng" sort="Qiu, Feng" uniqKey="Qiu F" first="Feng" last="Qiu">Feng Qiu</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sykora, Kathy" sort="Sykora, Kathy" uniqKey="Sykora K" first="Kathy" last="Sykora">Kathy Sykora</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shulman, Kenneth I" sort="Shulman, Kenneth I" uniqKey="Shulman K" first="Kenneth I." last="Shulman">Kenneth I. Shulman</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Psychiatry, Sunnybrook and Women's College Health Sciences Centre, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Kunin–Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><idno type="ISSN">0885-3185</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antipsychotic</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Cohort Studies</term>
<term>Databases, Factual (statistics & numerical data)</term>
<term>Drug Utilization Review (statistics & numerical data)</term>
<term>Female</term>
<term>Geriatric Assessment</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson disease</term>
<term>Psychosis</term>
<term>Psychotic Disorders (drug therapy)</term>
<term>Psychotic Disorders (epidemiology)</term>
<term>Psychotic Disorders (etiology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Databases, Factual</term>
<term>Drug Utilization Review</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cohort Studies</term>
<term>Female</term>
<term>Geriatric Assessment</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antipsychotique</term>
<term>Parkinson maladie</term>
<term>Psychose</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The choice of agents to treat psychotic symptoms in Parkinson's disease is important given the potential for antipsychotics to worsen Parkinsonism. The purpose of this study was to estimate the incidence of psychotic symptoms requiring treatment in individuals with Parkinson's disease after starting dopaminergic medications, and to describe the agents being selected as initial antipsychotic therapy. Using the administrative health care databases of Ontario, Canada, individuals 66 years of age or older with Parkinson's disease who were newly treated with dopaminergic agents were identified. Subsequent prescriptions for antipsychotic medications were then identified. A total of 10,347 older adults were newly started on dopaminergic agents between 1998 and 2003. The Kaplan–Meier estimate for the cumulative probability of requiring an antipsychotic at 7 years was 35%; 499 individuals (4.8%; 5.2/100 person–years) were prescribed an antipsychotic within 1 year of starting dopaminergic therapy. The proportion of initial antipsychotic prescriptions for typical antipsychotics decreased from 56% (42 of 75) in 1998 to 9% (8 of 88) in 2002. Antipsychotic use is common in individuals with Parkinsonism newly treated with dopaminergic medication. Typical antipsychotics are still commonly being chosen as first‐line agents for older patients, indicating a need for interventions to improve practice. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2007:Marras C:antipsychotic:use:in"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Antipsychotic use in older adults with parkinson's disease</title>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Institute for Clinical Evaluative Sciences</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Medicine, University of Toronto</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Kopp, Alexander" sort="Kopp, Alexander" uniqKey="Kopp A" first="Alexander" last="Kopp">Alexander Kopp</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Institute for Clinical Evaluative Sciences</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Feng Qiu" sort="Feng Qiu" uniqKey="Feng Qiu" last="Feng Qiu">FENG QIU</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Institute for Clinical Evaluative Sciences</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Medicine, University of Toronto</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Sykora, Kathy" sort="Sykora, Kathy" uniqKey="Sykora K" first="Kathy" last="Sykora">Kathy Sykora</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Institute for Clinical Evaluative Sciences</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shulman, Kenneth I" sort="Shulman, Kenneth I" uniqKey="Shulman K" first="Kenneth I." last="Shulman">Kenneth I. Shulman</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Medicine, University of Toronto</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Psychiatry, Sunnybrook and Women's College Health Sciences Centre</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Institute for Clinical Evaluative Sciences</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Medicine, University of Toronto</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Kunin-Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0181687</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0181687 INIST</idno>
<idno type="RBID">Pascal:07-0181687</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000762</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000558</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000674</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000674</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Marras C:antipsychotic:use:in</idno>
<idno type="wicri:Area/Main/Merge">002964</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Antipsychotic use in older adults with parkinson's disease</title>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Institute for Clinical Evaluative Sciences</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Medicine, University of Toronto</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Kopp, Alexander" sort="Kopp, Alexander" uniqKey="Kopp A" first="Alexander" last="Kopp">Alexander Kopp</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Institute for Clinical Evaluative Sciences</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Feng Qiu" sort="Feng Qiu" uniqKey="Feng Qiu" last="Feng Qiu">FENG QIU</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Institute for Clinical Evaluative Sciences</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Medicine, University of Toronto</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Sykora, Kathy" sort="Sykora, Kathy" uniqKey="Sykora K" first="Kathy" last="Sykora">Kathy Sykora</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Institute for Clinical Evaluative Sciences</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shulman, Kenneth I" sort="Shulman, Kenneth I" uniqKey="Shulman K" first="Kenneth I." last="Shulman">Kenneth I. Shulman</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Medicine, University of Toronto</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Psychiatry, Sunnybrook and Women's College Health Sciences Centre</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Institute for Clinical Evaluative Sciences</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Medicine, University of Toronto</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Kunin-Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antipsychotic</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Psychosis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Psychose</term>
<term>Antipsychotique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The choice of agents to treat psychotic symptoms in Parkinson's disease is important given the potential for antipsychotics to worsen Parkinsonism. The purpose of this study was to estimate the incidence of psychotic symptoms requiring treatment in individuals with Parkinson's disease after starting dopaminergic medications, and to describe the agents being selected as initial antipsychotic therapy. Using the administrative health care databases of Ontario, Canada, individuals 66 years of age or older with Parkinson's disease who were newly treated with dopaminergic agents were identified. Subsequent prescriptions for antipsychotic medications were then identified. A total of 10,347 older adults were newly started on dopaminergic agents between 1998 and 2003. The Kaplan-Meier estimate for the cumulative probability of requiring an antipsychotic at 7 years was 35%; 499 individuals (4.8%; 5.2/100 person-years) were prescribed an antipsychotic within 1 year of starting dopaminergic therapy. The proportion of initial antipsychotic prescriptions for typical antipsychotics decreased from 56% (42 of 75) in 1998 to 9% (8 of 88) in 2002. Antipsychotic use is common in individuals with Parkinsonism newly treated with dopaminergic medication. Typical antipsychotics are still commonly being chosen as first-line agents for older patients, indicating a need for interventions to improve practice.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="no"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antipsychotic use in older adults with Parkinson's disease</title>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
</author>
<author><name sortKey="Kopp, Alexander" sort="Kopp, Alexander" uniqKey="Kopp A" first="Alexander" last="Kopp">Alexander Kopp</name>
</author>
<author><name sortKey="Qiu, Feng" sort="Qiu, Feng" uniqKey="Qiu F" first="Feng" last="Qiu">Feng Qiu</name>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</author>
<author><name sortKey="Sykora, Kathy" sort="Sykora, Kathy" uniqKey="Sykora K" first="Kathy" last="Sykora">Kathy Sykora</name>
</author>
<author><name sortKey="Shulman, Kenneth I" sort="Shulman, Kenneth I" uniqKey="Shulman K" first="Kenneth I." last="Shulman">Kenneth I. Shulman</name>
</author>
<author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:0C3F9C4EA52476687FAD7642CB4ED5E3CF6DD2D6</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/mds.21192</idno>
<idno type="url">https://api-v5.istex.fr/document/0C3F9C4EA52476687FAD7642CB4ED5E3CF6DD2D6/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000046</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000046</idno>
<idno type="wicri:Area/Istex/Curation">000046</idno>
<idno type="wicri:Area/Istex/Checkpoint">000978</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000978</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Marras C:antipsychotic:use:in</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17149718</idno>
<idno type="wicri:Area/PubMed/Corpus">001094</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001094</idno>
<idno type="wicri:Area/PubMed/Curation">001094</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001094</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001094</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001094</idno>
<idno type="wicri:Area/Ncbi/Merge">000712</idno>
<idno type="wicri:Area/Ncbi/Curation">000712</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000712</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Marras C:antipsychotic:use:in</idno>
<idno type="wicri:Area/Main/Merge">002743</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Centre, Toronto Western Hospital, 7 McL, 399 Bathurst Street, Toronto, ON M5T 2S8</wicri:regionArea>
<wicri:noRegion>ON M5T 2S8</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kopp, Alexander" sort="Kopp, Alexander" uniqKey="Kopp A" first="Alexander" last="Kopp">Alexander Kopp</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Qiu, Feng" sort="Qiu, Feng" uniqKey="Qiu F" first="Feng" last="Qiu">Feng Qiu</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sykora, Kathy" sort="Sykora, Kathy" uniqKey="Sykora K" first="Kathy" last="Sykora">Kathy Sykora</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shulman, Kenneth I" sort="Shulman, Kenneth I" uniqKey="Shulman K" first="Kenneth I." last="Shulman">Kenneth I. Shulman</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Psychiatry, Sunnybrook and Women's College Health Sciences Centre, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Kunin–Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><idno type="ISSN">0885-3185</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Cohort Studies</term>
<term>Databases, Factual (statistics & numerical data)</term>
<term>Drug Utilization Review (statistics & numerical data)</term>
<term>Female</term>
<term>Geriatric Assessment</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Psychotic Disorders (drug therapy)</term>
<term>Psychotic Disorders (epidemiology)</term>
<term>Psychotic Disorders (etiology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Databases, Factual</term>
<term>Drug Utilization Review</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cohort Studies</term>
<term>Female</term>
<term>Geriatric Assessment</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The choice of agents to treat psychotic symptoms in Parkinson's disease is important given the potential for antipsychotics to worsen Parkinsonism. The purpose of this study was to estimate the incidence of psychotic symptoms requiring treatment in individuals with Parkinson's disease after starting dopaminergic medications, and to describe the agents being selected as initial antipsychotic therapy. Using the administrative health care databases of Ontario, Canada, individuals 66 years of age or older with Parkinson's disease who were newly treated with dopaminergic agents were identified. Subsequent prescriptions for antipsychotic medications were then identified. A total of 10,347 older adults were newly started on dopaminergic agents between 1998 and 2003. The Kaplan–Meier estimate for the cumulative probability of requiring an antipsychotic at 7 years was 35%; 499 individuals (4.8%; 5.2/100 person–years) were prescribed an antipsychotic within 1 year of starting dopaminergic therapy. The proportion of initial antipsychotic prescriptions for typical antipsychotics decreased from 56% (42 of 75) in 1998 to 9% (8 of 88) in 2002. Antipsychotic use is common in individuals with Parkinsonism newly treated with dopaminergic medication. Typical antipsychotics are still commonly being chosen as first‐line agents for older patients, indicating a need for interventions to improve practice. © 2006 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002500 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002500 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:0C3F9C4EA52476687FAD7642CB4ED5E3CF6DD2D6 |texte= Antipsychotic use in older adults with Parkinson's disease }}
This area was generated with Dilib version V0.6.29. |